EPZ6438 (Tazemetostat) is a potent and selective SAM-competitive EZH2 inhibitor (EZH2i), approved by the FDA to treat patients with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection [46]. Here, EZH2 is linked to epithelioid sarcoma.